Gilead Sciences, Inc. (GILD) 2022 5th Annual Evercore ISI HealthCONx Conference(Transcript)Seeking Alpha • 11/30/22
European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric PopulationsBusiness Wire • 11/29/22
These Are the Five Best and Worst Performing Healthcare Stocks in October 202224/7 Wall Street • 11/29/22
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That SurgesInvestors Business Daily • 11/28/22
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung CancerBusiness Wire • 11/28/22
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung CancerBusiness Wire • 11/28/22
Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Santa Claus Rally24/7 Wall Street • 11/28/22
See Why Gilead's Cancer Business Is Driving The Stock To A Fever PitchInvestors Business Daily • 11/23/22
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022Business Wire • 11/03/22
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric PatientsBusiness Wire • 11/02/22
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver DiseaseBusiness Wire • 11/01/22